Bayer: adjusted EPS down 37% in Q3
(CercleFinance.com) - Bayer reports a 36.
8% drop in Q3 2024 adjusted EPS (excluding exceptional items) to E0.24, as well as a 25.8% drop in adjusted EBITDA to E1.25bn, i.e. a margin that is down 3.7 points to 12.6%.
At E9.97bn, sales were down 3.6% overall, but up 0.6% in organic terms, with a 3.6% decline in agrochemicals more than offset by growth in pharmaceuticals (+2.3%) and consumer health (+5.7%).
The development of the agricultural market was weaker than expected, particularly in Latin America, and the company also continues to face price pressure in the crop protection sector, CEO Bill Anderson says.
Bayer confirms all its forecasts at group level for 2024, apart from its adjusted EBITDA, which it now expects between E10.4bn and E10.7bn (vs. E10.7bn to E11.3bn), due to the weakness of the agricultural market.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
8% drop in Q3 2024 adjusted EPS (excluding exceptional items) to E0.24, as well as a 25.8% drop in adjusted EBITDA to E1.25bn, i.e. a margin that is down 3.7 points to 12.6%.
At E9.97bn, sales were down 3.6% overall, but up 0.6% in organic terms, with a 3.6% decline in agrochemicals more than offset by growth in pharmaceuticals (+2.3%) and consumer health (+5.7%).
The development of the agricultural market was weaker than expected, particularly in Latin America, and the company also continues to face price pressure in the crop protection sector, CEO Bill Anderson says.
Bayer confirms all its forecasts at group level for 2024, apart from its adjusted EBITDA, which it now expects between E10.4bn and E10.7bn (vs. E10.7bn to E11.3bn), due to the weakness of the agricultural market.
Copyright (c) 2024 CercleFinance.com. All rights reserved.